Literature DB >> 15175327

A proteomic study of SUMO-2 target proteins.

Alfred C O Vertegaal1, Stephen C Ogg, Ellis Jaffray, Manuel S Rodriguez, Ronald T Hay, Jens S Andersen, Matthias Mann, Angus I Lamond.   

Abstract

The SUMO family in vertebrates includes at least three distinct proteins (SUMO-1, -2, and -3) that are added as post-translational modifications to target proteins. A considerable number of SUMO-1 target proteins have been identified, but little is known about SUMO-2. A stable HeLa cell line expressing His6-tagged SUMO-2 was established and used to label and purify novel endogenous SUMO-2 target proteins. Tagged forms of SUMO-2 were functional and localized predominantly in the nucleus. His6-tagged SUMO-2 conjugates were affinity-purified from nuclear fractions and identified by mass spectrometry. Eight novel potential SUMO-2 target proteins were identified by at least two peptides. Three of these proteins, SART1, heterogeneous nuclear ribonucleoprotein (RNP) M, and the U5 small nuclear RNP 200-kDa helicase, play a role in RNA metabolism. SART1 and heterogeneous nuclear RNP M were both shown to be genuine SUMO targets, confirming the validity of the approach.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15175327     DOI: 10.1074/jbc.M404201200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

1.  High-stringency tandem affinity purification of proteins conjugated to ubiquitin-like moieties.

Authors:  Filip Golebiowski; Michael H Tatham; Akihiro Nakamura; Ronald T Hay
Journal:  Nat Protoc       Date:  2010-04-15       Impact factor: 13.491

2.  SUMOylation pathway in Trypanosoma cruzi: functional characterization and proteomic analysis of target proteins.

Authors:  Julio C Bayona; Ernesto S Nakayasu; Marc Laverrière; Clemente Aguilar; Tiago J P Sobreira; Hyungwon Choi; Alexey I Nesvizhskii; Igor C Almeida; Juan J Cazzulo; Vanina E Alvarez
Journal:  Mol Cell Proteomics       Date:  2011-08-10       Impact factor: 5.911

3.  A universal strategy for proteomic studies of SUMO and other ubiquitin-like modifiers.

Authors:  Germán Rosas-Acosta; William K Russell; Adeline Deyrieux; David H Russell; Van G Wilson
Journal:  Mol Cell Proteomics       Date:  2004-11-30       Impact factor: 5.911

Review 4.  SUMO wrestling with type 1 diabetes.

Authors:  Manyu Li; Dehuang Guo; Carlos M Isales; Decio L Eizirik; Mark Atkinson; Jin-Xiong She; Cong-Yi Wang
Journal:  J Mol Med (Berl)       Date:  2005-04-02       Impact factor: 4.599

Review 5.  Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics.

Authors:  Donald S Kirkpatrick; Carilee Denison; Steven P Gygi
Journal:  Nat Cell Biol       Date:  2005-08       Impact factor: 28.824

6.  Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress.

Authors:  Robert C A M van Waardenburg; David M Duda; Cynthia S Lancaster; Brenda A Schulman; Mary-Ann Bjornsti
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

7.  An extended consensus motif enhances the specificity of substrate modification by SUMO.

Authors:  Shen-Hsi Yang; Alex Galanis; James Witty; Andrew D Sharrocks
Journal:  EMBO J       Date:  2006-10-12       Impact factor: 11.598

Review 8.  Dissecting the ubiquitin pathway by mass spectrometry.

Authors:  Ping Xu; Junmin Peng
Journal:  Biochim Biophys Acta       Date:  2006-09-14

9.  Sumoylation in axons triggers retrograde transport of the RNA-binding protein La.

Authors:  Erna A van Niekerk; Dianna E Willis; Jay H Chang; Kerstin Reumann; Tilman Heise; Jeffery L Twiss
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-23       Impact factor: 11.205

10.  Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.

Authors:  Ragu Kanagasabai; Shujun Liu; Samir Salama; Edith F Yamasaki; Liwen Zhang; Kari B Greenchurch; Robert M Snapka
Journal:  Biochemistry       Date:  2009-04-14       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.